KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $359.0 million.

  • Esperion Therapeutics' Total Current Liabilities rose 11645.05% to $359.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.0 million, marking a year-over-year increase of 11645.05%. This contributed to the annual value of $246.2 million for FY2024, which is 5761.53% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Total Current Liabilities is $359.0 million, which was up 11645.05% from $298.8 million recorded in Q2 2025.
  • Esperion Therapeutics' Total Current Liabilities' 5-year high stood at $359.0 million during Q3 2025, with a 5-year trough of $73.4 million in Q4 2021.
  • Its 5-year average for Total Current Liabilities is $149.8 million, with a median of $107.2 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 2202.32% in 2021, then surged by 11645.05% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Total Current Liabilities stood at $73.4 million in 2021, then rose by 25.84% to $92.3 million in 2022, then soared by 69.24% to $156.2 million in 2023, then surged by 57.62% to $246.2 million in 2024, then surged by 45.81% to $359.0 million in 2025.
  • Its last three reported values are $359.0 million in Q3 2025, $298.8 million for Q2 2025, and $271.0 million during Q1 2025.